Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14279086 | 1.00 | DRD2 (0.67) | DRD2DRD4 | |
| SCHEMBL6777189 | 1.00 | DRD2 (0.67) | DRD2DRD4 | |
| SCHEMBL6777191 | 1.00 | DRD2 (0.67) | DRD2DRD4 | |
| SCHEMBL4873282 | 0.90 | DRD2 (0.65) | DRD2DRD4 | |
| SCHEMBL4873294 | 0.90 | DRD2 (0.65) | DRD2DRD4 | |
| SCHEMBL7171948 | 0.90 | DRD2 (0.54) | DRD2DRD4 | |
| SCHEMBL7171953 | 0.90 | DRD2 (0.54) | DRD2DRD4 | |
| SCHEMBL4875242 | 0.89 | DRD2 (0.69) | DRD2DRD4 | |
| SCHEMBL4875246 | 0.89 | DRD2 (0.69) | DRD2DRD4 | |
| SCHEMBL14279082 | 0.89 | DRD2 (0.59) | DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191136-A1 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION | 2003-10-09 | — | — | US | claimed |
| US-20020052383-A1 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION | 2002-05-02 | — | — | US | claimed |
| US-7323478-B2 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323478-B2 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION (US) | 2008-01-29 | — | — | US | disclosed |
| US-6753336-B2 | EATING DISORDERS; SEXUAL DISORDERS | NEUROGEN CORPORATION | 2004-06-22 | — | — | US | disclosed |
| US-20030191136-A1 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION | 2003-10-09 | — | — | US | disclosed |
| US-6569861-B2 | Phenylcycloalkylmethylamino and phenylalkenylamino derivatives, including 1-phenyl-2-aminomethylcyclopropanes; treatment of a variety of metabolic, feeding, and sexual disorders including obesity. | NEUROGEN CORPORATION | 2003-05-27 | — | — | US | disclosed |
| US-20020052383-A1 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052383-A1 | Melanin concentrating hormone receptor ligands | MCHR1, NPY1R, MCHR2 | DRD2 152/4885DRD4 250/4885 |
| US-20030191136-A1 | Melanin concentrating hormone receptor ligands | MCHR1, NPY1R, MCHR2 | DRD2 153/4885DRD4 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.